Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 11696579
Du XL, et al. (2001) Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108, 1341-8 11696579
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S1177-p - eNOS (human)
Modsite: TSRIRtQsFsLQERQ SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S1177‑p, eNOS (mouse): S1176‑p, eNOS (rat): S1176‑p, eNOS (rabbit): S1183‑p, eNOS (pig): S1179‑p, eNOS (cow): S1179‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  primary cultured cells
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hyperglycemia decrease
hyperglycemia decrease
wortmannin hyperglycemia augment treatment-induced decrease

S1177-gl - eNOS (human)
Modsite: TSRIRtQsFsLQERQ SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S1177‑gl, eNOS (mouse): S1176‑gl, eNOS (rat): S1176‑gl, eNOS (rabbit): S1183‑gl, eNOS (pig): S1179‑gl, eNOS (cow): S1179‑gl
Characterization
Methods used to characterize site in vivo mutation of modification site
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hyperglycemia increase

S1176-p - eNOS (rat)
Modsite: TSRIRtQsFsLQERQ SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S1177‑p, eNOS (mouse): S1176‑p, eNOS (rat): S1176‑p, eNOS (rabbit): S1183‑p, eNOS (pig): S1179‑p, eNOS (cow): S1179‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  vascular
Cellular systems studied:  tissue
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hyperglycemia decrease

S1179-p - eNOS (cow)
Modsite: TSRIRtQsFsLQERH SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S1177‑p, eNOS (mouse): S1176‑p, eNOS (rat): S1176‑p, eNOS (rabbit): S1183‑p, eNOS (pig): S1179‑p, eNOS (cow): S1179‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  BAEC (endothelial)
Cellular systems studied:  primary cultured cells
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hyperglycemia decrease
wortmannin hyperglycemia augment treatment-induced decrease